Who is sponsoring NCT03696030?

NCT03696030 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT03696030?

Interventions in NCT03696030: Chimeric Antigen Receptor T-Cell Therapy.

What condition does NCT03696030 study?

NCT03696030 studies Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer.

Is NCT03696030 still recruiting?

NCT03696030 is currently active, enrolled. Last updated 13 April 2025.

Last reviewed 2025-04-13 · How we verify

NCT03696030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

Active, enrolled Phase 1 Last updated 13 April 2025

What this trial tests

Phase 1 trial testing Chimeric Antigen Receptor T-Cell Therapy in Malignant Neoplasm in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 August 2018

Primary endpoint
19 February 2026

19 February 2026

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	31 August 2018
Primary completion	19 February 2026
Estimated completion	19 February 2026
Sites	1 location across United States

Drugs / interventions tested

Chimeric Antigen Receptor T-Cell Therapy — full drug profile →

Conditions studied

Malignant Neoplasm — all drugs for Malignant Neoplasm →
Metastatic Malignant Neoplasm in the Brain — all drugs for Metastatic Malignant Neoplasm in the Brain →
Metastatic Malignant Neoplasm in the Leptomeninges — all drugs for Metastatic Malignant Neoplasm in the Leptomeninges →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

City of Hope Medical Center

Who can join

Adults 18 to 75, any sex, with Malignant Neoplasm or Metastatic Malignant Neoplasm in the Brain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent). HER2-CAR T cells delivered into the ventricles of the brain may recognize and kill tumor cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell therapy: current limitations and potential strategies.
Sterner RC, Sterner RM. · · 2021 · cited 1883× · PMID 33824268 · DOI 10.1038/s41408-021-00459-7
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M, Moon EK. · · 2019 · cited 653× · PMID 30804938 · DOI 10.3389/fimmu.2019.00128
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.
Ye F, Dewanjee S, Li Y, Jha NK, et al · · 2023 · cited 361× · PMID 37415164 · DOI 10.1186/s12943-023-01805-y
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J, Wickman E, DeRenzo C, Gottschalk S. · · 2020 · cited 284× · PMID 32979309 · DOI 10.1016/j.ymthe.2020.09.015
Engineered T Cell Therapy for Cancer in the Clinic.
Zhao L, Cao YJ. · · 2019 · cited 275× · PMID 31681259 · DOI 10.3389/fimmu.2019.02250
Differentiation and Regulation of T<sub>H</sub> Cells: A Balancing Act for Cancer Immunotherapy.
Basu A, Ramamoorthi G, Albert G, Gallen C, et al · · 2021 · cited 260× · PMID 34012451 · DOI 10.3389/fimmu.2021.669474
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
Salemme V, Centonze G, Cavallo F, Defilippi P, et al · · 2021 · cited 194× · PMID 33777750 · DOI 10.3389/fonc.2021.610303
CAR T cells for brain tumors: Lessons learned and road ahead.
Akhavan D, Alizadeh D, Wang D, Weist MR, et al · · 2019 · cited 172× · PMID 31355493 · DOI 10.1111/imr.12773

Verify or expand the search:

Other trials of Chimeric Antigen Receptor T-Cell Therapy

Trials testing the same drug.

NCT06784726 — Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · Phase 2 · recruiting
NCT06815029 — Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress · Phase 1 · recruiting
NCT06834373 — Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C · Phase 2 · recruiting
NCT05993611 — Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic G · Phase 1 · suspended
NCT05800405 — Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B- · EARLY_PHASE1 · recruiting

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03696030 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 13 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03696030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing